Moleculin Biotech Stock Buy Hold or Sell Recommendation
| MBRX Stock | USD 1.13 0.03 2.59% |
Given the investment horizon of 90 days and your above-average risk tolerance, our recommendation regarding Moleculin Biotech is 'Hold'. A buy or sell recommendation is an automated directive regarding whether to purchase or sell Moleculin Biotech given historical horizon and risk tolerance. When we issue a 'buy' or 'sell' recommendation for Moleculin Biotech, the advice is generated through an automated system that utilizes algorithms and statistical models.
Check out Moleculin Biotech Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. For more information on how to buy Moleculin Stock please use our How to Invest in Moleculin Biotech guide. In addition, we conduct extensive research on individual companies such as Moleculin and provide practical buy, sell, or hold advice based on investors' investing horizon and their risk tolerance towards Moleculin Biotech. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.
Moleculin |
Execute Moleculin Biotech Buy or Sell Advice
The Moleculin recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Moleculin Biotech. Macroaxis does not own or have any residual interests in Moleculin Biotech or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Moleculin Biotech's advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Hold
Market Performance | Insignificant | Details | |
Volatility | Extremely Dangerous | Details | |
Hype Condition | Over hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Low | Details | |
Economic Sensitivity | Hyperactively responds to market trends | Details | |
Investor Sentiment | Impartial | Details | |
Analyst Consensus | Buy | Details | |
Financial Strenth (F Score) | Poor | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Moleculin Biotech Trading Alerts and Improvement Suggestions
| Moleculin Biotech is way too risky over 90 days horizon | |
| Moleculin Biotech may become a speculative penny stock | |
| Moleculin Biotech appears to be risky and price may revert if volatility continues | |
| Net Loss for the year was (29.77 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Moleculin Biotech currently holds about 58 M in cash with (24.1 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.03, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Moleculin Biotech has a poor financial position based on the latest SEC disclosures | |
| Latest headline from thelincolnianonline.com: Disposition of 1053 shares by Foster Jonathan P. of Moleculin Biotech at 3.74 subject to Rule 16b-3 |
Moleculin Biotech Returns Distribution Density
The distribution of Moleculin Biotech's historical returns is an attempt to chart the uncertainty of Moleculin Biotech's future price movements. The chart of the probability distribution of Moleculin Biotech daily returns describes the distribution of returns around its average expected value. We use Moleculin Biotech price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Moleculin Biotech returns is essential to provide solid investment advice for Moleculin Biotech.
| Mean Return | 0.80 | Value At Risk | -17.65 | Potential Upside | 14.72 | Standard Deviation | 28.08 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Moleculin Biotech historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
Moleculin Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument, such as Moleculin Biotech, soars without any apparent reason? This usually happens because many institutional investors are aggressively trading Moleculin Biotech back and forth among themselves.
| Shares | Morgan Stanley - Brokerage Accounts | 2024-12-31 | 426 | Sbi Securities Co Ltd | 2024-12-31 | 405 | Bogart Wealth, Llc | 2024-12-31 | 300 | Bank Of America Corp | 2024-12-31 | 104 | Sandy Spring Bank | 2024-12-31 | 89.0 | Cva Family Office, Llc | 2024-12-31 | 34.0 | Kestra Investment Management, Llc | 2024-12-31 | 25.0 | North Star Investment Management Corp | 2024-12-31 | 17.0 | Northern Trust Investments N A | 2024-12-31 | 0.0 | Armistice Capital, Llc | 2024-12-31 | 317.6 K | Lpl Financial Corp | 2024-12-31 | 41.2 K |
Moleculin Biotech Cash Flow Accounts
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Change In Cash | 4.4M | 55.7M | (27.8M) | (19.6M) | (17.6M) | (16.8M) | |
| Free Cash Flow | (18.1M) | (19.0M) | (27.7M) | (24.2M) | (21.8M) | (22.9M) | |
| Depreciation | 200K | 164K | 130K | 127K | 146.1K | 112.9K | |
| Other Non Cash Items | 85K | 96K | (1.2M) | 1.9M | 2.2M | 2.3M | |
| Capital Expenditures | 376K | 19K | 67K | 124K | 142.6K | 137.6K | |
| Net Income | (17.4M) | (15.9M) | (29.0M) | (29.8M) | (26.8M) | (25.5M) | |
| End Period Cash Flow | 15.2M | 70.9M | 43.1M | 23.6M | 27.1M | 22.4M | |
| Change To Netincome | (2.0M) | (2.5M) | (575K) | (4.3M) | (3.8M) | (3.6M) | |
| Investments | (374K) | (19K) | (67K) | (43K) | (49.5K) | (51.9K) |
Moleculin Biotech Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Moleculin Biotech or Biotechnology sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Moleculin Biotech's price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Moleculin stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | 1.36 | |
β | Beta against Dow Jones | 5.24 | |
σ | Overall volatility | 29.08 | |
Ir | Information ratio | 0.03 |
Moleculin Biotech Volatility Alert
Moleculin Biotech is showing large volatility of returns over the selected time horizon. Moleculin Biotech is a potential penny stock. Although Moleculin Biotech may be in fact a good instrument to invest, many penny stocks are speculative in nature and are subject to artificial price hype. Please make sure you totally understand the upside potential and downside risk of investing in Moleculin Biotech. We encourage investors to look for signals such as email spams, message board hypes, claims of breakthroughs, volume upswings, sudden news releases, promotions that are not reported, or demotions released before SEC filings. Please also check biographies and work history of current and past company officers before investing in high volatility instruments, penny stocks, or equities with microcap classification. You can indeed make money on Moleculin instrument if you perfectly time your entry and exit. However, remember that penny stocks that have been the subject of artificial hype usually unable to maintain their increased share price for more than just a few days. The price of a promoted high volatility instrument will almost always revert back. The only way to increase shareholder value is through legitimate performance backed up by solid fundamentals.Moleculin Biotech Fundamentals Vs Peers
Comparing Moleculin Biotech's fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Moleculin Biotech's direct or indirect competition across all of the common fundamentals between Moleculin Biotech and the related equities. This way, we can detect undervalued stocks with similar characteristics as Moleculin Biotech or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Moleculin Biotech's fundamental indicators could also be used in its relative valuation, which is a method of valuing Moleculin Biotech by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Moleculin Biotech to competition |
| Fundamentals | Moleculin Biotech | Peer Average |
| Return On Equity | -1.41 | -0.31 |
| Return On Asset | -0.57 | -0.14 |
| Current Valuation | 4.91 M | 16.62 B |
| Shares Outstanding | 12.01 M | 571.82 M |
| Shares Owned By Insiders | 0.83 % | 10.09 % |
| Shares Owned By Institutions | 3.87 % | 39.21 % |
| Number Of Shares Shorted | 2.2 M | 4.71 M |
| Price To Earning | (3.81) X | 28.72 X |
| Price To Book | 1.86 X | 9.51 X |
| EBITDA | (29.5 M) | 3.9 B |
| Net Income | (29.77 M) | 570.98 M |
| Cash And Equivalents | 58 M | 2.7 B |
| Cash Per Share | 2.03 X | 5.01 X |
| Total Debt | 574 K | 5.32 B |
| Debt To Equity | 0.01 % | 48.70 % |
| Current Ratio | 10.47 X | 2.16 X |
| Book Value Per Share | 2.49 X | 1.93 K |
| Cash Flow From Operations | (24.1 M) | 971.22 M |
| Short Ratio | 0.08 X | 4.00 X |
| Earnings Per Share | (12.04) X | 3.12 X |
| Target Price | 18.0 | |
| Number Of Employees | 18 | 18.84 K |
| Beta | 1.94 | -0.15 |
| Market Capitalization | 13.57 M | 19.03 B |
| Total Asset | 38.22 M | 29.47 B |
| Retained Earnings | (131.6 M) | 9.33 B |
| Working Capital | 19.46 M | 1.48 B |
| Current Asset | 28.09 K | 9.34 B |
| Current Liabilities | 772.79 K | 7.9 B |
| Net Asset | 38.22 M |
Note: Acquisition by Foster Jonathan P. of 162667 shares of Moleculin Biotech subject to Rule 16b-3 [view details]
Moleculin Biotech Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Moleculin . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
About Moleculin Biotech Buy or Sell Advice
When is the right time to buy or sell Moleculin Biotech? Buying financial instruments such as Moleculin Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having Moleculin Biotech in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Obamacare Thematic Idea Now
Obamacare
Health care services and providers including hospitals, clinics and nursing homes that hope to benefit from Obamacare program. The Obamacare theme has 37 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Obamacare Theme or any other thematic opportunities.
| View All Next | Launch |
Additional Tools for Moleculin Stock Analysis
When running Moleculin Biotech's price analysis, check to measure Moleculin Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Moleculin Biotech is operating at the current time. Most of Moleculin Biotech's value examination focuses on studying past and present price action to predict the probability of Moleculin Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Moleculin Biotech's price. Additionally, you may evaluate how the addition of Moleculin Biotech to your portfolios can decrease your overall portfolio volatility.